Other chemotherapy regimens including mitoxantrone and suramin.
This article reviews the role of systemic chemotherapy in the treatment of hormone refractory prostate cancer, with emphasis on the evidence regarding the use of mitoxantrone plus prednisone, suramin, and various investigational regimens. Outcome assessment in this disease has not been uniform; recently evolved measures such as patient-based "palliative" endpoints and prostate-specific antigen responses will be discussed.
Siu
L L
LL
Department of Medicine, Princess Margaret Comprehensive Cancer Centre, University of Toronto, Ontario, Canada.
Moore
M J
MJ
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage* / Q000627:therapeutic use; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013498:Suramin / Q000008:administration & dosage* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013498:Suramin; D004317:Doxorubicin; D003520:Cyclophosphamide; D008942:Mitoxantrone